Program
brivaracetam
Also written as “Brivaracetam”, “Brivaracetam Film-coated tablet” and “Brivaracetam oral solution”.
Its studies are mostly in Epilepsy · Epilepsy, Absence · Epilepsies, Partial · Myoclonus · Seizures, led by 4 companies.
Drug pageBrivaracetam: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCBits history only | 392 open or running | phase 3since Sep 6, 2005 | Sep 6, 2005 | Nov 16, 2029phase 3 · NCT06315322 |
| Overseas Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 11, 2022 | Nov 11, 2022 | none ahead |
| Qingfeng Pharmaceutical Group | 10 open or running | phase 3since Apr 17, 2026 | Apr 17, 2026 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 1since Dec 23, 2024 | Dec 23, 2024 | none ahead |
Also a collaborator on its studies: PRA Health Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Qingfeng Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2026First study: phase 3 study in Epilepsies, PartialFirst studyNCT07563634 · 141 enrolled · China
TargetBeta
“Synaptic vesicle glycoprotein 2A modulator”ChEMBL 37, by rule
Other programs on SV2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Levetiracetamrule | UCB | phase 4 | 73 |
Studies
The one study Qingfeng Pharmaceutical Group leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07563634Epilepsies, Partial · China | 3 | Completed | May 21, 2024 | 141 |
How it is read
Names in the registry
- “Brivaracetam”, 33 entries
- “brivaracetam”, 3 entries
- “Brivaracetam Film-coated tablet”, 2 entries
- “Brivaracetam oral solution”, 2 entries
- “Brivaracetam 25 mg”, 2 entries
Conditions, from the studies’ own filings
- Epilepsy, 28 studies
- Epilepsy, Absence, 3 studies
- Epilepsies, Partial, 2 studies
- Myoclonus, 2 studies
- Seizures, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.